Ground-breaking assay platform for neurodegenerative disease research

Progressive neuronal cell loss within the human brain is the pathological hallmark of several neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Insights into the early processes triggering the neurodegenerative disease cascade is fundamental to the development of highly differentiated therapeutics for these diseases.

With our new and patent-protected assay platform, we create highly relevant disease models and innovative assays for functional and morphological investigations. The platform is based on a newly developed microfluidics concept that enables local interventions in compartmentalized in vitro neuronal circuits. For example, we can model prion-like spreading of neurodegenerative disease associated peptides in CNS neuronal circuits.

We engage with our Clients to establish screening programs, where functional and morphological screening assays are applied for the identification of novel targets and unique lead compounds, to achieve new treatment options for neurodegenerative diseases.

Assaying neuronal function in neuropsychiatric disorders

Our synaptic function assays are enabling the discovery and development of highly differentiated therapeutics for neuropsychiatric disorders.

Current strategies for the identification of synaptic drug targets or compounds require either a significant sacrifice in assay throughput or a gross, non-physiological simplification of the model system. Our technology platform eliminates this trade-off, allowing for higher throughput screening while retaining the ability to measure synaptic communication between neurons.

The platform enables high capacity testing of changes in both excitability and synaptic communication in native neuronal cultures, and our functional assays fill the gap between less complex model systems, such as high throughput screening in over-expressing cell lines, and in vivo animal models. We can also couple these with downstream high content analysis assays to provide complementary data on cellular and network morphology.

Paul Karila
Head of Drug Discovery

“By combining our expertise in microfluidics, high-content imaging and optical electrophysiology with in vitro neuronal models, we create high capacity assay platforms enabling efficient screening and profiling of larger compound sets in the search for new drug candidates for neurodegenerative diseases.”
Contact us arrow_forwards